RxDoctor Payments DataLook up a doctor →

Steven Lupovitch, MD

Cardiovascular Disease · Arlington Heights, ILNPI 1710901889

Payments from drug & device makers

$2,635,611in general payments, 2019–2025

Across 1,438 payments — averaging $1832.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$1M
  • Novartis$470K
  • Eli Lilly$321K
  • Amgen$280K
  • Boehringer Ingelheim International GmbH$181K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$125K
  • plus $250K from 34 others
$36,654in research payments, 2019–2025

Across 21 payments — averaging $1745.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vifor (international) Ltd.$34K
  • Eli Lilly$3K

What the payments were for

  • Food & beverage$2,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,635,611 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$399,744
Medicare patients
2,855
Services billed
6,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,058$1,378,764
XareltoRivaroxaban180$218,789
EntrestoSacubitril/Valsartan110$151,204
OzempicSemaglutide79$118,839
JardianceEmpagliflozin68$88,450
Repatha SureclickEvolocumab76$83,105
WegovySemaglutide27$56,078
MounjaroTirzepatide32$51,895
VascepaIcosapent Ethyl36$35,010
MultaqDronedarone Hcl19$31,801
Icosapent Ethyl54$30,891
Praluent PenAlirocumab26$27,201
Rosuvastatin Calcium1,526$23,260
LivaloPitavastatin Calcium19$18,051
Repatha SyringeEvolocumab19$17,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,449$1,378,7641,058 claims
Johnson & JohnsonXarelto$432$218,789180 claims
Novo NordiskOzempic, Wegovy$148$174,917106 claims
NovartisEntresto$469,888$151,204110 claims
Boehringer IngelheimJardiance$31,701$88,45068 claims
AstraZenecaFarxiga, Crestor$53,246$19,40623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →